Related Experiment Video
Updated: Sep 21, 2025
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
A chloroacetamide derivative as a potent candidate for fusariosis treatment
Gabriella da Rosa Monte Machado1,2, Stefânia Neiva Lavorato3, William Lopes4
1Graduate Program in Agricultural Microbiology and Environment, Federal University of Rio Grande Do Sul, Sarmento Leite no 500 - Farroupilha, Porto Alegre, RS, 90050-170, Brazil. gabbirosam@gmail.com.
Abstract:
Fusariosis has presented a significant increase in their incidence in the last years. This epidemiological panorama probably is due to the increasing profile of refractory susceptibility of Fusarium spp. to available drugs, especially in immunocompromised individuals. Thus, the development of new compounds with effectiveness on these organisms is a necessity. This study evaluated the antifungal potential of a chloroacetamide derivative (4-BFCA) against resistant Fusarium strains. As a result, the compound was effective against all strains (MIC range 12.5-50 μg/mL). The time kill assay demonstrated that 4-BFCA presents a concentration-dependent fungicidal action. Although its action mechanism has not yet been elucidated, it was possible to observe its efficacy through damages and alterations provoked along the hyphae of Fusarium spp. 4-BFCA maintained a high survival rate of Tenebrio molitor larvae, suggesting that it does not cause acute systemic toxicity on this host at the concentration evaluated. In addition, 4-BFCA was 83.33% effective in combating a fungal infection in vivo on the chorioallantoid membrane of embryonated eggs. Our results are very promising and arouse interest to investigate the action of 4-BFCA on Fusarium strains since it acts as a possible candidate for the development of new therapies for the treatment of fusariosis.
Insights
A new compound, 4-BFCA, shows promise in treating fusariosis by effectively killing resistant Fusarium strains. This antifungal agent demonstrated efficacy in vitro and in vivo, suggesting potential for new therapies.
Area of Science:
- Mycology
- Infectious Diseases
- Medicinal Chemistry
Background:
- Fusariosis incidence is rising, driven by Fusarium species' resistance to existing antifungal drugs.
- Immunocompromised individuals are particularly vulnerable to invasive fusariosis.
- There is an urgent need for novel antifungal compounds to combat drug-resistant Fusarium infections.
Purpose of the Study:
- To evaluate the antifungal potential of a novel chloroacetamide derivative, 4-BFCA, against drug-resistant Fusarium strains.
- To assess the efficacy and safety of 4-BFCA in preclinical models.
Main Methods:
- Minimum Inhibitory Concentration (MIC) determination against resistant Fusarium strains.
- Time-kill assays to assess fungicidal activity.
- Toxicity assessment using Tenebrio molitor larvae.
- In vivo efficacy testing on the chorioallantoic membrane of embryonated eggs.
Main Results:
- 4-BFCA exhibited potent antifungal activity against all tested Fusarium strains, with MICs ranging from 12.5-50 μg/mL.
- The compound demonstrated concentration-dependent fungicidal action and caused observable hyphal damage.
- 4-BFCA showed no significant acute systemic toxicity in Tenebrio molitor larvae.
- An 83.33% efficacy rate was observed in combating fungal infections in vivo.
Conclusions:
- 4-BFCA is a promising candidate for developing new therapies against fusariosis.
- Further investigation into the mechanism of action of 4-BFCA is warranted.
- The compound's efficacy against resistant strains and favorable safety profile suggest therapeutic potential.
Related Concept Videos
01:11Aryldiazonium Salts to Azo Dyes: Diazo Coupling
01:23Amines to Sulfonamides: The Hinsberg Test
Generally, a primary amine reacts with the Hinsberg reagent to produce an N-substituted benzenesulfonamide. The electron-withdrawing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD